Skip to main content
. Author manuscript; available in PMC: 2024 Feb 6.
Published in final edited form as: Int J Cancer. 2023 Sep 11;154(3):454–464. doi: 10.1002/ijc.34726

Table 2.

ChemRICH set enrichment analysis to identify lipid set associated with liver cancer risk.

Lipid Class p-value (ChemRICH) FDR (ChemRICH) Significant lipids (FDR < 0.05) Significant lipids (%) Set Size Positive associations (FDR <0.05) Negative Associations (FDR < 0.05)
UFA-TAG (Triacylglycerol) 2.7E-15 7.5E-14 20 43% 47 17 3
SM (Sphingomyelin) 3.2E-12 4.4E-11 12 80% 15 1 11
UFA-SM (Sphingomyelin 5.8E-12 5.4E-11 14 70% 20 0 14
SFA-TAG (Triacylglycerol) 1.0E-11 7.2E-11 7 58% 12 7 0
MUFA-TAG (Triacylglycerol) 3.3E-11 1.8E-10 12 57% 21 12 0
CER (Ceramide) 7.9E-11 3.7E-10 15 58% 26 2 13
CE (Cholesterol ester) 3.2E-10 1.3E-09 7 64% 11 1 6
UFA-PC (Phosphatidylcholine 2.0E-09 6.9E-09 9 27% 33 8 1
plasmPC (Plasmalogen phosphatidylcholine) 3.2E-08 1.0E-07 7 16% 44 1 6
PUFA-TAG (Triacylglycerol) 1.9E-07 5.2E-07 7 16% 44 4 3
UFA-LPC (Lysophosphatidylcholine) 3.0E-06 7.7E-06 3 75% 4 0 3
MUFA (Monounsaturated fatty acid) 1.8E-05 4.1E-05 4 57% 7 4 0
MUFA-PC(Phosphatidylcholine) 9.8E-05 2.1E-04 5 56% 9 5 0
PUFA-PC (Phosphatidylcholine) 1.1E-04 2.1E-04 8 21% 38 5 3
PUFA-LPC (Lysophosphatidylcholine) 4.3E-04 8.0E-04 4 80% 5 0 4
SFA-LPC (Lysophosphatidylcholine) 5.5E-04 9.6E-04 3 30% 10 0 3
PE (Phosphatidylethanolamine) 1.0E-02 1.7E-02 2 20% 10 2 0
AC (Acylcarnitine) 1.3E-02 2.0E-02 2 18% 11 2 0
SFA-PC (Phosphatidylcholine) 2.2E-02 3.3E-02 2 25% 8 2 0
DG (Diglyceride) 2.6E-02 3.6E-02 4 44% 9 2 2
PI (Phosphatidylinositol) 3.1E-02 4.1E-02 3 38% 8 3 0
GlcCer (Glucosylceramide) 3.5E-02 4.4E-02 3 38% 8 1 2

MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid, UFA, unsaturated fatty acid.